» Articles » PMID: 38023817

Visualization of Ferroptosis in Brain Diseases and Ferroptosis-inducing Nanomedicine for Glioma

Overview
Date 2023 Nov 29
PMID 38023817
Authors
Affiliations
Soon will be listed here.
Abstract

A remarkable body of new data establishes that many degenerative brain diseases and some acute injury situations in the brain may be associated with ferroptosis. In recent years, ferroptosis has also attracted great interest in the cancer research community, partly because it is a unique mode of cell death distinct from other forms and thus has great therapeutic potential for brain cancer. Glioblastoma is a highly aggressive and fatal human cancer, accounting for 60% of all primary brain tumors. Despite the development of various pharmacological and surgical modalities, the survival rates of high-grade gliomas have remained poor over the past few decades. Recent evidence has revealed that ferroptosis is involved in tumor initiation, progression, and metastasis, and manipulating ferroptosis could offer a novel strategy for glioma management. Nanoparticles have been exploited as multifunctional platforms that can cross the blood-brain barrier and deliver therapeutic agents to the brain to address the pressing need for accurate visualization of ferroptosis and glioma treatment. To create efficient and durable ferroptosis inducers, many researchers have engineered nanocomposites to induce a more effective ferroptosis for therapy. In this review, we present the mechanism of ferroptosis and outline the current strategies of imaging and nanotherapy of ferroptosis in brain diseases, especially glioma. We aim to provide up-to-date information on ferroptosis and emphasize the potential clinical implications of ferroptosis for glioma diagnosis and treatment. However, regulation of ferroptosis in vivo remains challenging due to a lack of compounds.

Citing Articles

Nanoparticle Strategies for Treating CNS Disorders: A Comprehensive Review of Drug Delivery and Theranostic Applications.

Toader C, Dumitru A, Eva L, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2025; 25(24.

PMID: 39769066 PMC: 11676454. DOI: 10.3390/ijms252413302.


Ferroptosis: emerging roles in lung cancer and potential implications in biological compounds.

Liang Q, Wang Y, Li Y, Wang J, Liu C, Li Y Front Pharmacol. 2024; 15:1374182.

PMID: 38783959 PMC: 11111967. DOI: 10.3389/fphar.2024.1374182.

References
1.
Qi Y, Wang H, Chen L, Duan Y, Yang S, Zhu H . Recent advances in small-molecule fluorescent probes for studying ferroptosis. Chem Soc Rev. 2022; 51(18):7752-7778. DOI: 10.1039/d1cs01167g. View

2.
Li B, Chen X, Qiu W, Zhao R, Duan J, Zhang S . Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. Adv Sci (Weinh). 2022; 9(17):e2105451. PMC: 9189685. DOI: 10.1002/advs.202105451. View

3.
Chen Q, Wang Y, Yue T, Wei H, Li S, Dong B . Fluorescence Imaging of Intracellular Glutathione Levels in the Endoplasmic Reticulum to Reveal the Inhibition Effect of Rutin on Ferroptosis. Anal Chem. 2023; . DOI: 10.1021/acs.analchem.2c04209. View

4.
LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

5.
Tsoi J, Robert L, Paraiso K, Galvan C, Sheu K, Lay J . Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018; 33(5):890-904.e5. PMC: 5953834. DOI: 10.1016/j.ccell.2018.03.017. View